SEC Form 4 · accession 0001144204-16-139620
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabrielle Alison Silver
Director
Period of report
Dec 13, 2016
Accepted (ET)
Dec 15, 2016 · 11:24 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.00 | Dec 13, 2016 | A | 11,667 | A | Dec 13, 2016 | May 16, 2021 | Common Stock | 11,667 | 11,667 | D |
Explanation of responses
- F1On May 17, 2016, the reporting person was granted an option to purchase 35,000 shares of common stock. The option vests as follows: (i) 11,667 shares vest upon the uplisting of the Company to the NASDAQ Stock Market, (ii) 11,667 shares vest upon the cumulative funding of the Company of or in excess of $5,000,000 by institutional investors commencing May 5, 2016 and (iii) 11,666 shares vest upon the first submission of a New Drug Application to the U.S. Food and Drug Administration for one of the Company's products by either the Company or a Company licensee. On December 13, 2016, the performance criteria in subsection (ii) was met, resulting in vesting of the option as to 11,667 shares.